MUMBAI (Reuters) - Asia's largest vaccine maker, the Serum Institute of India Ltd, is in talks with private equity firms to sell a stake of as much as 10 percent in the unlisted group, Bloomberg reported on Friday.
Bloomberg, citing Chief Executive Officer Adar Poonawalla, said the group was in discussions with funds in the United States and Singapore. The report said Serum is seeking a valuation of as much as 800 billion Indian rupees ($12.16 billion).
(http://bloom.bg/1MggT0W)
Indian newspapers had reported in June that the Poonawalla family could sell as much as 20 percent of the group to a long-term fund, after shelving plans for a market listing.
A spokesman for Serum was not immediately reachable for comment.
($1 = 65.8150 rupees)
(Reporting by Karen Rebelo and Zeba Siddiqui; Editing by Muralikumar Anantharaman)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
